ARK Genomic Revolution ETF
ARKG
80 hedge funds and large institutions have $103M invested in ARK Genomic Revolution ETF in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
11% more funds holding
Funds holding: 72 → 80 (+8)
2.56% more ownership
Funds ownership: 22.91% → 25.46% (+2.6%)
2% less capital invested
Capital invested by funds: $105M → $103M (-$1.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$4.05M |
| 2 |
CAN
Claraphi Advisory Network
Aliso Viejo,
United States
|
+$2.56M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.51M |
| 4 |
Morgan Stanley
New York
|
+$1.73M |
| 5 |
HT
HAP Trading
New York
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$3.22M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$537K |
| 3 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
-$293K |
| 4 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
-$291K |
| 5 |
SCA
Snowden Capital Advisors
New York
|
-$281K |
ARKG Hedge Fund Activity: Q3 2019 in Review
80 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q3 2019, worth a combined $103M — down 1.9% from $105M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ARKG positions and 5 closed out — a net gain of 8 holders — while 30 added to existing stakes and 17 trimmed.
The largest buyer was Raymond James & Associates, adding an estimated $4.05M. The largest seller was Stephens Inc, cutting an estimated $3.22M.
- 80 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q3 2019, up from 72 in Q2 2019.
- Funds reported $103M of ARK Genomic Revolution ETF stock for Q3 2019, down 1.9% quarter-over-quarter.
- 13 funds opened new ARK Genomic Revolution ETF positions in Q3 2019 and 5 closed out, a net change of +8 holders.
- The largest ARK Genomic Revolution ETF buyer in Q3 2019 was Raymond James & Associates, an estimated $4.05M added.
- The largest ARK Genomic Revolution ETF seller in Q3 2019 was Stephens Inc, an estimated $3.22M sold.
Based on aggregated 13F filings for Q3 2019.